{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T04:11:40Z","timestamp":1744863100980,"version":"3.40.4"},"reference-count":15,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2025,4,1]]},"abstract":"Importance<\/jats:title>Variation in nicastrin (NCSTN<\/jats:italic>) is associated with a monogenic subtype of hidradenitis suppurativa. Dysregulation of humoral immunity has been suggested as a potential mechanistic link between NCSTN<\/jats:italic> variation and hidradenitis suppurativa. There is a paucity of biomarkers that can predict disease-associated variation.<\/jats:p><\/jats:sec>Objective<\/jats:title>To investigate whether serum immunoglobulin levels, as a surrogate marker of humoral immunity, can identify individuals with hidradenitis suppurativa who have a specific disease-associated NCSTN<\/jats:italic> variant.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>Maltese individuals with hidradenitis suppurativa genotyped for a disease-associated NCSTN<\/jats:italic> in-frame deletion prevalent in the local patient cohort were invited to participate in this cross-sectional study from January to July 2023. Participation was restricted to adult individuals with hidradenitis suppurativa without known or suspected pathologies that would be associated with serum immunoglobulin levels. Data were analyzed between October 2023 and December 2023.<\/jats:p><\/jats:sec>Exposure<\/jats:title>Serum immunoglobulin G levels and other hematological paraments were analyzed.<\/jats:p><\/jats:sec>Main Outcome and Measure<\/jats:title>Main outcomes were the associations between serum immunoglobulin levels and an underlying NCSTN<\/jats:italic> variation in individuals with hidradenitis suppurativa.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 125 individuals (64 female individuals [51.2%]) with hidradenitis suppurativa of Maltese ethnicity were recruited in the study, of whom 17 (13.6%) who were from 7 genealogically unrelated families were heterozygous for the disease-associated NCSTN<\/jats:italic> variant. Deletion carriers had a higher serum immunoglobulin G level (1370 mg\/dL vs 1140 mg\/dL [to convert to g\/L, multiply by 0.01]; P<\/jats:italic>\u2009&amp;lt;\u2009.001). The association between NCSTN<\/jats:italic> variation and elevated immunoglobulin G levels retained significance despite adjusting for multiple confounders, including markers of disease severity, age of recruitment, age of disease onset, treatment with adalimumab, and liver transaminase levels. Serum immunoglobulin G demonstrated a strong discriminatory capacity in identifying patients who were heterozygous for the NCSTN<\/jats:italic> variant.<\/jats:p><\/jats:sec>Conclusion and Relevance<\/jats:title>The results of this cross-sectional study suggest an altered humoral immune state in patients harboring a specific NCSTN<\/jats:italic> variant and support the role of serum immunoglobulin G levels as a potential predictive biomarker of monogenic hidradenitis suppurativa. This may aid in identifying and prioritizing individuals with monogenic hidradenitis suppurativa.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamadermatol.2024.5684","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T17:41:11Z","timestamp":1738172471000},"page":"411","source":"Crossref","is-referenced-by-count":0,"title":["Serum Immunoglobulin G Levels and Nicastrin Variation in Hidradenitis Suppurativa"],"prefix":"10.1001","volume":"161","author":[{"given":"Dillon","family":"Mintoff","sequence":"first","affiliation":[{"name":"Department of Pathology, Faculty of Medicine and Surgery, University of Malta, Malta"},{"name":"Department of Dermatology, Mater Dei Hospital, Msida, Malta"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolai P.","family":"Pace","sequence":"additional","affiliation":[{"name":"Centre for Molecular Medicine and Biobanking, University of Malta, Malta"},{"name":"Department of Anatomy, Faculty of Medicine and Surgery, University of Malta, Malta"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"5","key":"dbr240024r1","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/j.jid.2019.08.453","article-title":"Enrichment of plasma cells in the peripheral blood and skin of patients with hidradenitis suppurativa.","volume":"140","author":"Musilova","year":"2020","journal-title":"J Invest Dermatol"},{"issue":"3","key":"dbr240024r2","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1111\/bjd.19805","article-title":"Differential profiles of gamma secretase Notch signaling in hidradenitis suppurativa: the need for genotype-endotype-phenotype analysis.","volume":"185","author":"Frew","year":"2021","journal-title":"Br J Dermatol"},{"issue":"4","key":"dbr240024r3","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.jid.2017.09.051","article-title":"Hidradenitis suppurativa-like lesions associated with pharmacologic inhibition of gamma-secretase.","volume":"138","author":"O\u2019Sullivan Coyne","year":"2018","journal-title":"J Invest Dermatol"},{"issue":"74","key":"dbr240024r4","first-page":"493","article-title":"Serum immunoglobulins in patients with chronic hepatitis C: a surrogate marker of disease severity and treatment outcome.","volume":"54","author":"Maruyama","year":"2007","journal-title":"Hepatogastroenterology"},{"issue":"3","key":"dbr240024r5","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1001\/jamadermatol.2021.4926","article-title":"Identification of biomarkers and critical evaluation of biomarker validation in hidradenitis suppurativa: a systematic review.","volume":"158","author":"Der Sarkissian","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"9","key":"dbr240024r6","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1001\/jamadermatol.2023.2227","article-title":"NCSTN in-frame deletion in Maltese patients with hidradenitis suppurativa.","volume":"159","author":"Mintoff","year":"2023","journal-title":"JAMA Dermatol"},{"issue":"6","key":"dbr240024r7","first-page":"517","article-title":"Consensus of a group of professional societies and diagnostic companies on guidelines for interim reference ranges for 14 proteins in serum based on the standardization against the IFCC\/BCR\/CAP Reference Material (CRM 470).","volume":"34","author":"Dati","year":"1996","journal-title":"Eur J Clin Chem Clin Biochem"},{"issue":"8","key":"dbr240024r8","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1515\/CCLM.2011.624","article-title":"N Latex FLC\u2014new monoclonal high-performance assays for the determination of free light chain kappa and lambda.","volume":"49","author":"Velthuis","year":"2011","journal-title":"Clin Chem Lab Med"},{"issue":"6","key":"dbr240024r9","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1007\/s10875-023-01518-3","article-title":"Inborn errors of immunity in hidradenitis suppurativa pathogenesis and disease burden.","volume":"43","author":"Colvin","year":"2023","journal-title":"J Clin Immunol"},{"issue":"9","key":"dbr240024r10","doi-asserted-by":"publisher","first-page":"4894","DOI":"10.1073\/pnas.1916645117","article-title":"Essential requirement for nicastrin in marginal zone and B-1 B cell development.","volume":"117","author":"Choi","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"dbr240024r11","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jid.2023.05.013","article-title":"The Hidradenitis Suppurativa Omics Database (HS-OmicsDB).","volume":"144","author":"Dimitrion","year":"2024","journal-title":"J Invest Dermatol"},{"issue":"1","key":"dbr240024r12","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/j.1365-2133.2011.10643.x","article-title":"Alterations in leucocyte subsets and histomorphology in normal-appearing perilesional skin and early and chronic hidradenitis suppurativa lesions.","volume":"166","author":"van der Zee","year":"2012","journal-title":"Br J Dermatol"},{"issue":"3","key":"dbr240024r13","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.169870","article-title":"Tertiary lymphoid structures sustain cutaneous B cell activity in hidradenitis suppurativa.","volume":"9","author":"Lowe","year":"2024","journal-title":"JCI Insight"},{"issue":"4","key":"dbr240024r14","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.jaad.2023.05.076","article-title":"A proof-of-concept open-label clinical trial of spleen tyrosine kinase antagonism using fostamatinib in moderate-to-severe hidradenitis suppurativa.","volume":"89","author":"Jepsen","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"dbr240024r15","doi-asserted-by":"publisher","first-page":"e116","DOI":"10.1111\/1346-8138.14144","article-title":"Successful treatment of hidradenitis suppurativa with rituximab for a patient with idiopathic carpotarsal osteolysis and chronic active antibody-mediated rejection.","volume":"45","author":"Takahashi","year":"2018","journal-title":"J Dermatol"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2829499\/jamadermatology_mintoff_2025_br_240024_1744811633.44103.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T15:01:04Z","timestamp":1744815664000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2829499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2024.5684","relation":{},"ISSN":["2168-6068"],"issn-type":[{"type":"print","value":"2168-6068"}],"subject":[],"published":{"date-parts":[[2025,4,1]]}}}